




Patent Docket P0709P1D3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | |
|------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| In re Application of Paul J. Carter et al. Serial No.: 09/705,686 Filed: November 2, 2000 For: METHOD FOR MAKING HUMANIZED ANTIBODIES | Group Art Unit: 1642 Examiner: L. Helms CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and is addressed to: U.S. Patent and Trademark Office, Washington, D.C. 20231-9999 Express Mail No. EL 889 330 681 US March 18, 2002  Wendy M. Lee |
|------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

STATEMENT OF RELATED CASES

Assistant Commissioner of Patents
Washington, D.C. 20231


Sir:

The following applications are related to the above-identified application:

- U.S. Application Serial No. 08/146,206, filed November 17, 1993;
- U.S. Application Serial No. 09/115,800, filed July 15, 1998;
- U.S. Application Serial No. 09/366,004, filed August 2, 1999;
- U.S. Application Serial No. 09/705,392, filed November 2, 2000; and
- U.S. Application Serial No. 09/705,398, filed November 2, 2000.

Respectfully submitted,
GENENTECH, INC.

Date: March 18, 2002

By: 
Wendy M. Lee
Reg. No. 40,378
Telephone: (650) 225-1994



09157

PATENT TRADEMARK OFFICE

09/705/686

Sheet 01 of 13
RECEIVED

| | | | |
|---------------|-------------------------------------------------------|-------------------------------------------------------|----------------------------------------|
| FORM PTO-1449 | U.S. Dept. of Commerce Patent and Trademark Office | Atty Docket No. P0709P1D3 | Serial No. 02/2300 not yet assigned |
| | | Applicant 02 MAR 27 PM 12:58 Paul J. Carter et al. | |
| | | Filing Date 02 Nov 2000 | Group not yet assigned |

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

| Examiner Initials | Document Number | Date | Name | Class | Subclass | Filing Date |
|----------------------|-----------------|----------|----------------|-------|----------|-------------|
| | * 1 07/934,373 | | Carter et al. | | | 21.08.92 |
| | * 2 08/437,642 | | Carter et al. | | | 09.05.95 |
| | * 3 09/115,800 | | Carter et al. | | | 15.07.98 |
| | 4 4,753,894 | 28.06.88 | Frankel et al. | | | |
| | * 5 4,816,567 | 28.03.89 | Cabilly et al. | | | |
| | * 6 4,845,198 | 04.07.89 | Urdal et al. | | | |
| | * 7 5,132,405 | 21.07.92 | Huston et al. | | | |
| | 8 5,169,774 | 08.12.92 | Frankel et al. | | | |
| | * 9 5,225,539 | 06.07.93 | Winter, G. | | | |
| | * 10 5,530,101 | 25.06.96 | Queen et al. | | | 19.12.90 |
| | * 11 5,558,864 | 24.09.96 | Bendig et al. | | | |
| | * 12 5,585,089 | 17.12.96 | Queen et al. | | | 07.06.95 |
| | * 13 5,677,171 | 14.10.97 | Hudziak et al. | | | |
| | * 14 5,714,350 | 03.02.98 | Co et al. | | | 13.01.95 |
| | 15 5,720,937 | 24.02.98 | Hudziak et al. | | | |
| | 16 5,720,954 | 24.02.98 | Hudziak et al. | | | |
| | 17 5,725,856 | 10.03.98 | Hudziak et al. | | | |
| | 18 5,770,195 | 23.05.98 | Hudziak et al. | | | |
| | * 19 5,772,997 | 30.06.98 | Hudziak et al. | | | |
| | * 20 5,821,337 | 13.10.98 | Carter et al. | | | |
| | * 21 5,859,205 | 12.01.99 | Adair et al. | | | 07.09.94 |
| | 22 6,054,561 | 25.04.00 | Ring | | | 07.06.95 |

FOREIGN PATENT DOCUMENTS

| Examiner Initials | Document Number | Date | Country | Class | Subclass | Translation Yes No |
|----------------------|-------------------|----------|-----------|-------|----------|-----------------------|
| | * 23 85058/91 | 30.03.92 | AUSTRALIA | | | |
| | * 24 0 460 167 B1 | 11.12.91 | EPO | | | |
| | * 25 0 519 596 A1 | 23.12.92 | EPO | | | |
| | * 26 0 592 106 A1 | 13.04.94 | EPO | | | |
| | * 27 120,694 | 03.10.84 | EPO | | | |
| | * 28 125,023 A1 | 14.11.84 | EPO | | | |
| | * 29 239,400 | 30.09.87 | EPO | | | |
| | * 30 323,806 A1 | 12.07.89 | EPO | | | |
| | * 31 328,404 A1 | 16.08.89 | EPO | | | |
| | * 32 338,745 A1 | 25.10.89 | EPO | | | |
| | * 33 365,209 A2 | 25.04.90 | EPO | | | |

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

09/205,686

| | | | |
|----------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|------------------------------------|--------------------------------|
| FORM PTO-1449 LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary) | U.S. Dept. of Commerce Patent and Trademark Office | Atty Docket No. P0709P1D3 | Serial No. not yet assigned |
| | | Applicant Paul J. Carter et al. | |
| | | Filing Date 02 Nov 2000 | Group not yet assigned |

FOREIGN PATENT DOCUMENTS

| Examiner Initials | | Document Number | Date | Country | Class | Subclass | Translation Yes No | |
|-------------------|---|-----------------|----------|----------------|-------|----------|--------------------------|--|
| | * | 34 365,997 A2 | 02.05.90 | EPO | | | | |
| | * | 35 368,684 | 16.05.90 | EPO | | | | |
| | * | 36 403,156 A1 | 19.12.90 | EPO | | | | |
| | * | 37 432,249 B1 | 25.09.96 | EPO | | | | |
| | * | 38 438,310 A2 | 24.07.91 | EPO | | | | |
| | * | 39 440,351 | 07.08.91 | EPO | | | | |
| | * | 40 451,216 B1 | 24.01.96 | EPO | | | | |
| | * | 41 620,276 | 19.10.94 | EPO | | | | |
| | * | 42 682,040 A1 | 15.11.95 | EPO | | | | |
| | * | 43 EP 438,312 | 24.07.91 | EPO | | | | |
| | * | 44 94/11509 | 26.05.94 | PCT | | | | |
| | * | 45 WO 87/02671 | 07.05.87 | PCT | | | | |
| | * | 46 WO 88/09344 | 01.12.88 | PCT | | | | |
| | * | 47 WO 89/01783 | 09.03.89 | PCT | | | | |
| | * | 48 WO 89/06692 | 27.07.89 | PCT | | | | |
| | * | 49 WO 89/09622 | | PCT | | | | |
| | * | 50 WO 90/07861 | 26.07.90 | PCT | | | | |
| | * | 51 WO 91/07492 | 30.05.91 | PCT | | | | |
| | * | 52 WO 91/07500 | 30.05.91 | PCT | | | | |
| | * | 53 WO 91/09966 | 11.07.91 | PCT | | | | |
| | * | 54 WO 91/09967 | 11.07.91 | PCT | | | | |
| | * | 55 WO 91/09968 | 11.07.91 | PCT | | | | |
| | * | 56 WO 92/01047 | 23.01.92 | PCT | | | | |
| | * | 57 WO 92/04380 | 19.03.92 | PCT | | | | |
| | * | 58 WO 92/04381 | 19.03.92 | PCT | | | | |
| | * | 59 WO 92/05274 | 02.04.92 | PCT | | | | |
| | * | 60 WO 92/11018 | 07.09.92 | PCT | | | | |
| | * | 61 WO 92/11383 | 09.07.92 | PCT | | | | |
| | * | 62 WO 92/15683 | 17.09.92 | PCT | | | | |
| | * | 63 WO 92/16562 | 01.10.92 | PCT | | | | |
| | * | 64 WO 92/22653 | 23.12.92 | PCT | | | | |
| | * | 65 WO 93/02191 | 04.02.93 | PCT | | | | |
| | * | 66 WO 94/12214 | 09.06.94 | PCT | | | | |
| | | 67 WO 99/60023 | 25.11.99 | PCT | | | | |
| | * | 68 2 188941 | 14.10.87 | UNITED KINGDOM | | | | |

| | |
|----------|-----------------|
| Examiner | Date Considered |
|----------|-----------------|

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | | | | | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|------------------------------------|--|--------------------------------|--|
| FORM PTO-1499 | | U.S. Dept. of Commerce Patent and Trademark Office | | Atty Docket No. P0709P1D3 | | Serial No. not yet assigned | |
| LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary) | | | | Applicant Paul J. Carter et al. | | | |
| | | | | Filing Date 02 Nov 2000 | | Group not yet assigned | |
| | | | | | | | |
| OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | | | |
| | 69 | Adair et al., "Humanization of the murine anti-human CD3 monoclonal antibody OKT3" <u>Hum. Antibod. Hybridomas</u> 5:41-47 (1994) | | | | | |
| | 70 | Amit et al., "Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 A Resolution" <u>Science</u> 233:747-753 (Aug 1986) | | | | | |
| | 71 | Amzel and Poljak, "Three-dimensional structure of immunoglobulins" <u>Ann. Rev. Biochem.</u> 48:961-967 (1979) | | | | | |
| | 72 | Amzel et al., "The Three Dimensional Structure of a Combining Region-Ligand Complex of Immunoglobulin NEW at 3.5-A Resolution" <u>Proc. Natl. Acad. Sci. USA</u> 71(4):1427-1430 (Apr 1974) | | | | | |
| | 73 | Baselga et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185HER2 Monoclonal Antibody in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer" <u>J. Clin. Oncol.</u> 14(3):737-744 (Mar 1996) | | | | | |
| | 74 | Beverley & Callard, "Distinctive functional characteristics of human "T" lymphocytes defined by E rosetting or a monoclonal anti-T cell antibody" <u>European Journal of Immunology</u> 11:329-334 (1981) | | | | | |
| | 75 | Bindon et al., "Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q" <u>Journal of Experimental Medicine</u> 168(1):127-142 (July 1988) | | | | | |
| | 76 | "Biosym Technologies" in New Products, Chemical Design Automation 3" (December 1988) | | | | | |
| | 77 | Bird et al., "Single-chain antigen-binding proteins" <u>Science</u> 242:423-426 (Oct 1988) | | | | | |
| | 78 | Boulianne et al., "Production of functional chimaeric mouse/human antibody" <u>Nature</u> 312:643-646 (December 13, 1984) | | | | | |
| | 79 | Brennan et al., "Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G ₁ fragments" <u>Science</u> 229:81-83 (July 1985) | | | | | |
| | 80 | Brown et al., "Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival" <u>Proc. Natl. Acad. Sci. USA</u> 88:2663-2667 (April 1991) | | | | | |
| | 81 | Brown, Jr. et al., "Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival" <u>Proc. Natl. Acad. Sci. USA</u> 88:2663-2667 (1991) | | | | | |
| | 82 | Brucoleri et al., "Structure of antibody hypervariable loops reproduced by a conformational search algorithm" <u>Nature</u> 335:564-568 (Oct 1988) | | | | | |
| | 83 | Brucoleri, "Structure of antibody hypervariable loops reproduced by a conformational search algorithm" <u>Nature</u> 336:266 (1988) | | | | | |
| | 84 | Bruggemann, M. et al., "Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies" <u>Journal of Experimental Medicine</u> 166:1351-1361 (1987) | | | | | |
| | 85 | Burgess et al., "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue" <u>Journal of Cell Biology</u> 111:2129-2138 (1990) | | | | | |
| | 86 | Caron et al., "Biological and Immunological Features of Humanized M195 (Anti-CD33) Monoclonal Antibodies" <u>Cancer Research</u> 52:6761-6767 (Dec 1992) | | | | | |
| | 87 | Carter et al., "High level Escherichia coli expression and production of a bivalent humanized antibody fragment" <u>Bio/Technology</u> 10:163-167 (1992) | | | | | |
| Examiner | | | | Date Considered | | | |
| *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |

09/105/68p

Sheet 04 of 13

| | | | | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|------------------------------------|--------------------------------|
| FORM PTO-1449 | | U.S. Dept. of Commerce Patent and Trademark Office | | Atty Docket No. P0709P1D3 | Serial No. not yet assigned |
| LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary) | | | | Applicant Paul J. Carter et al. | |
| | | | | Filing Date 02 Nov 2000 | Group not yet assigned |
| OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | |
| | * 88 | Carter et al., "Humanization of an anti-p185 ^{HER2} antibody for human cancer therapy" <u>Proc. Natl. Acad. Sci.</u> 89:4285-4289 (May 1992) | | | |
| | * 89 | Casale et al., "Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis" <u>J. Allergy Clin. Immunol.</u> 100:110-121 (1997) | | | |
| | * 90 | Cheetham, J., "Reshaping the antibody combining site by CDR replacement-tailoring or tinkering to fit?" <u>Protein Engineering</u> 2(3):170-172 (1988) | | | |
| | * 91 | Chothia & Lesk, "The relation between the divergence of sequence and structure in proteins" <u>EMBO Journal</u> 5(4):823-826 (1986) | | | |
| | * 92 | Chothia and Lesk, "Canonical structures for the hypervariable regions of immunoglobulins" <u>J. Mol. Biol.</u> 196(4):901-917 (1987) | | | |
| | * 93 | Chothia et al., "Domain Association in Immunoglobulin Molecules. The Packing of Variable Domains" <u>Journal of Molecular Biology</u> 186:651-663 (1985) | | | |
| | * 94 | Chothia et al., "Principles of protein-protein recognition" <u>Nature</u> 256:705-708 (1975) | | | |
| | * 95 | Chothia et al., "The predicted structure of immunoglobulin D1.3 and its comparison with the crystal structure" <u>Science</u> 233:755-758 (Aug. 15, 1986) | | | |
| | * 96 | Chothia et al., "Transmission of conformational change in insulin" <u>Nature</u> 302:500-505 (1983) | | | |
| | * 97 | Chothia, C. et al., "Conformations of immunoglobulin hypervariable regions" <u>Nature</u> 342(6252):877-883 (1989) | | | |
| | * 98 | Clark et al., "The improved lytic function and in vivo efficacy of monovalent monoclonal CD3 antibodies" <u>European Journal of Immunology</u> 19:381-388 (1989) | | | |
| | * 99 | Co & Queen, "Humanized antibodies for therapy" <u>Nature</u> 351:501-502 (Jun 1991) | | | |
| | *100 | Co et al., "Chimeric and Humanized Antibodies with Specificity for the CD33 Antigen" <u>J. of Immunology</u> 148(4):1149-1154 (Feb 1992) | | | |
| | *101 | Co et al., "Humanized Anti-Lewis Y Antibodies: In Vitro Properties and Pharmacokinetics in Rhesus Monkeys" <u>Cancer Research</u> 56:1118-1125 (Mar 1996) | | | |
| | *102 | Co et al., "Humanized antibodies for antiviral therapy" <u>Proc. Natl. Acad. Sci. USA</u> 88:2869-2873 (April 1991) | | | |
| | *103 | Colman et al., "Crystal and Molecular Structure of the Dimer of Variable Domains of the Bence-Jones Protein ROY" <u>J. Mol. Biol.</u> 116:73-79 (1977) | | | |
| | *104 | Colman et al., "Three-dimensional structure of a complex of antibody with influenza virus neuraminidase" <u>Nature</u> 326:358-363 (Mar 1987) | | | |
| | *105 | Cook et al., "A map of the human immunoglobulin V _H locus completed by analysis of the telomeric region of chromosome 14q" <u>Nature Genetics</u> 7:162-168 (Jun 1994) | | | |
| | *106 | Corti et al., "Idiotope Determining Regions of a Mouse Monoclonal Antibody and Its Humanized Versions" <u>J. Mol. Biol.</u> 235:53-60 (1994) | | | |
| | *107 | Coussens et al., "Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene" <u>Science</u> 230:1132-1139 (1985) | | | |
| Examiner | | | | Date Considered | |
| *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | |

| | | | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|--------------------------------|
| FORM PTO-1449 | | U.S. Dept. of Commerce Patent and Trademark Office | Atty Docket No. P0709P1D3 | Serial No. not yet assigned |
| LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary) | | | Applicant Paul J. Carter et al. | |
| | | | Filing Date 02 Nov 2000 | Group not yet assigned |
| OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) | | | | |
| | *108 | Couto et al., "Anti-BA46 Monoclonal Antibody Mc3 Humanization Using a Novel Positional Consensus and in Vivo and in Vitro Characterization" <u>Cancer Research Supplement</u> 55:1717-1722 (1995) | | |
| | *109 | Couto et al., "Humanization of KC4G3, an Anti-Human Carcinoma Antibody" <u>Hybridoma</u> 13:215-219 (1994) | | |
| | *110 | Darsley & Rees, "Nucleotide sequences of five anti-lysozyme monoclonal antibodies" <u>EMBO Journal</u> 4(2):393-398 (1985) | | |
| | *111 | Daugherty et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins" <u>Nucleic Acids Research</u> 19(9):2471-2476 (May 11, 1991) | | |
| | *112 | Davies & Metzger, "Structural Basis of Antibody Function" <u>Ann. Rev. Immunol.</u> 1:87-117 (1983) | | |
| | *113 | Davies et al., "Antibody-Antigen Complexes" <u>Journal of Biological Chemistry</u> 263(22):10541-10544 (Aug. 1988) | | |
| | *114 | Davies, D. R. et al., "Antibody-Antigen Complexes" <u>Ann. Rev. Biochem.</u> 59:439-473 (1990) | | |
| | *115 | Eigenbrot et al., "X-Ray Structures of Fragments From Binding and Nonbinding Versions of a Humanized Anti-CD18 Antibody: Structural Indications of the Key Role of V _H Residues 59 to 65" <u>Proteins: Structure, Function, and Genetics</u> 18:49-62 (1994) | | |
| | *116 | Eigenbrot et al., "X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling" <u>J. Mol. Biol.</u> 229:969-995 (1993) | | |
| | *117 | Ellis et al., "Engineered Anti-CD38 Monoclonal Antibodies for Immunotherapy of Multiple Myeloma" <u>The Journal of Immunology</u> pps. 925-937 (1995) | | |
| | *118 | Ellison et al., "The nucleotide sequence of a human immunoglobulin C _γ 1 gene" <u>Nucleic Acids Research</u> 10(13):4071-4079 (1982) | | |
| | *119 | Emery & Adair, "Humanised monoclonal antibodies for therapeutic applications" <u>Exp. Opin. Invest. Drugs</u> 3(3):241-251 (1994) | | |
| | *120 | Epp et al., "Crystal and Molecular Structure of a Dimer Composed of the Variable Portions of the Bence-Jones Protein REI" <u>European Journal of Biochemistry</u> 45:513-524 (1974) | | |
| | *121 | Epp et al., "The molecular structure of a dimer composed of the variable portions of the Bence-Jones protein REI refined at 2.0-A resolution" <u>Biochemistry</u> 14(22):4943-4952 (1975) | | |
| | *122 | Fahy et al., "The Effect of an Anti-IgE Monoclonal Antibody on the Early- and Late-Phase Responses to Allergen Inhalation in Asthmatic Subjects" <u>Am J. Respir. Crit. Care Med</u> 155:1828-1834 (1997) | | |
| | *123 | Fanger et al., "Bispecific antibodies and targeted cellular cytotoxicity" <u>Immunology Today</u> 12(2):51-54 (1991) | | |
| | *124 | Fanger et al., "Cytotoxicity mediated by human Fc receptors for IgG" <u>Immunology Today</u> 10(3):92-99 (1989) | | |
| | *125 | Feldmann et al., "A Hypothetical Space-Filling Model of the V-Regions of the Galactan-Binding Myeloma Immunoglobulin J539" <u>Molecular Immunology</u> 18(8):683-698 (1981) | | |
| | *126 | Fendley et al., "The Extracellular Domain of HER2/neu is a Potential Immunogen for Active Specific Immunotherapy of Breast Cancer" <u>J. Biol. Resp. Mod.</u> 9:449-455 (1990) | | |
| | *127 | Fendly et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product" <u>Cancer Research</u> 50:1550-1558 (Mar 1, 1990) | | |
| Examiner | | | Date Considered | |
| *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | |

09/705686

Sheet 06 of 13

| | | | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|--------------------------------|
| FORM PTO-1449 | | U.S. Dept. of Commerce Patent and Trademark Office | Atty Docket No. P0709P1D3 | Serial No. not yet assigned |
| LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary) | | | Applicant Paul J. Carter et al. | |
| | | | Filing Date 02 Nov 2000 | Group not yet assigned |
| OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) | | | | |
| | *128 | Foote et al., "Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops" <u>J. Mol. Biol.</u> 224:487-499 (1992) | | |
| | *129 | Foote, J., "Humanized Antibodies" <u>Nova acta Leopoldina</u> 61(269):103-110 (1989) | | |
| | *130 | Furey et al., "Structure of a novel Bence-Jones protein (Rhe) fragment at 1.6 A resolution" <u>J. Mol. Biol.</u> 167(3):661-692 (July 5, 1983) | | |
| | *131 | Glennie et al., "Preparation and Performance of Bispecific F(ab') ₂ Antibody Containing Thioether-Linked Fab'γ Fragments" <u>J. Immunol.</u> 139(7):2367-2375 (October 1, 1987) | | |
| | *132 | Gonzalez et al., "Humanization of Murine 6G425: An Anti-IL8 Monoclonal Antibody Which Blocks Binding of IL8 to Human Neutrophils" 1996 Keystone Symposia on Exploring and Exploiting Antibody and Ig Superfamily Combining Sites (Poster) pps. 1-21 (February 1996) | | |
| | *133 | Gorman et al., "Reshaping a therapeutic CD4 antibody" <u>Proc. Natl. Acad. Sci. USA</u> 88(10):4181-4185 (May 15, 1991) | | |
| | *134 | Gregory et al., "The solution conformations of the subclasses of human IgG deduced from sedimentation and small angle X-ray scattering studies" <u>Molecular Immunology</u> 24(8):821-829 (August 1987) | | |
| | *135 | Gussow & Seemann, "Humanization of Monoclonal Antibodies" <u>Meth. Enzymology</u> , Academic Press, Inc. Vol. 203:99-121 (1991) | | |
| | *136 | Hale, G. et al., "Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H" <u>Lancet</u> 2(8625):1394-1399 (Dec 17, 1988) | | |
| | *137 | Harris et al., "Therapeutic Antibodies - The Coming of Age" <u>TIBTECH</u> 11:42-44 (February 1993) | | |
| | *138 | Hieter et al., "Cloned human and mouse kappa immunoglobulin constant and J region genes conserve homology in functional segments" <u>Cell</u> 22(Part 1):197-207 (1980) | | |
| | *139 | Hieter et al., "Evolution of Human Immunoglobulin K J Region Genes" <u>The Journal of Biological Chemistry</u> 257:1516-1522 (1982) | | |
| | *140 | Houghton, A., "Building a better monoclonal antibody" <u>Immunology Today</u> 9(9):265-267 (1988) | | |
| | *141 | Huber et al., "Crystallographic structure studies of an IgG molecule and an Fc fragment" <u>Nature</u> 264:415-420 (December 2, 1976) | | |
| | *142 | Hudziak et al., "p185HER2 Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor" <u>Molecular & Cellular Biology</u> 9(3):1165-1172 (Mar 1989) | | |
| | *143 | Huston et al., "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli" <u>Proc. Natl. Acad. Sci. USA</u> 85:5879-5883 (Aug 1988) | | |
| | *144 | Isaacs et al., "Humanised Monoclonal Antibody Therapy for Rheumatoid Arthritis" <u>Lancet</u> 340:748-752 (September 26, 1992) | | |
| | *145 | Jaffers et al., "Monoclonal Antibody Therapy, Anti-Idiotypic and Non-Anti-Idiotypic Antibodies to OKT3 Arising Despite Intense Immunosuppression" <u>Transplantation</u> 41(5):572-578 (May 1986) | | |
| | *146 | Johnson et al., "Biological and Molecular Modeling Studies Comparing Murine Monoclonal Antibodies with Their Engineered Chimeric and Humanized Counterparts" <u>J. Cell. Biochem. Suppl</u> 0 (13 Part A) (18th Ann. UCLA Symp on Mol. & Cell. Biol., Park City, UT 1/17-22/89) pps. 87 (1989) | | |
| | *147 | Jones et al., "Replacing the Complementarity-determining Regions in a Human Antibody with Those From a Mouse" <u>Nature</u> 321:522-525 (May 29, 1986) | | |
| Examiner | | | Date Considered | |
| *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | |

USCOMM-DC 80-398.

09/705,684

Sheet 07 of 13

| | | | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|--------------------------------|
| FORM PTO-1449 | | U.S. Dept. of Commerce Patent and Trademark Office | Atty Docket No. P0709P1D3 | Serial No. not yet assigned |
| LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary) | | | Applicant Paul J. Carter et al. | |
| | | | Filing Date 02 Nov 2000 | Group not yet assigned |
| OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) | | | | |
| | *148 | Junghans et al., "Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor with New Features for Immunotherapy in Malignant and Immune Disorders" <u>Cancer Research</u> 50(5):1495-1502 (March 1, 1990) | | |
| | *149 | Kabat E., "Origins of Antibody Complementarity and Specificity - Hypervariable Regions and the Minigenes Hypothesis" <u>J. of Immunology</u> 125(3):961-969 (Sep 1980) | | |
| | *150 | Kabat et al. <u>Sequences of Proteins of Immunological Interest</u> , Bethesda, MD:National Institutes of Health pps. iii-xxiii, 41-76 and 160-167 (1987) | | |
| | *151 | Kabat et al. <u>Sequences of Proteins of Immunological Interest</u> , U.S. Dept. of Health and Human Services, NIH, 5th edition Vol. 1:103-108, 324-331 (1991) | | |
| | *152 | Kabat et al., "Sequences of Proteins of Immunological Interest", Bethesda, MD:National Institute of Health pps. 14-32 (1983) | | |
| | *153 | Kabat et al., "Sequences of Proteins of Immunological Interest, 4th Edition" pps. iii-xxvii, 41-76, 160-175 (1987) | | |
| | *154 | Kettleborough et al., "Humanization of a Mouse Monoclonal Antibody by CDR-grafting: the Importance of Framework Residues on Loop Conformation" <u>Protein Engineering</u> 4(7):773-783 (1991) | | |
| | *155 | Kindt & Capra <u>The Antibody Enigma</u> , New York:Plenum Press pps. 79-86 (1984) | | |
| | *156 | King et al., "Amplification of a Novel v-erbB-Related Gene in a Human Mammary Carcinoma" <u>Science</u> 229:974-976 (Sept 1985) | | |
| | *157 | Lazar et al., "Transforming Growth Factor α : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities" <u>Molecular & Cellular Biology</u> 8(3):1247-1252 (Mar. 1988) | | |
| | *158 | Lesk & Chothia, "Evolution of Proteins Formed by β -Sheets" <u>J. Mol. Biol.</u> 160:325-342 (1982) | | |
| | *159 | Lesk & Chothia, "The response of protein structures to amino-acid sequence changes" <u>Phil. Trans. R. Soc. Lond. A</u> 317:345-356 (1986) | | |
| | *160 | Lesk, Arthur M., "How Different Amino Acid Sequences Determine Similar Protein Structures: The Structure and Evolutionary Dynamics of the Globins" <u>J. Mol. Biol.</u> 136:225-270 (1980) | | |
| | *161 | Love et al, "Recombinant antibodies possessing novel effector functions" <u>Methods in Enzymology</u> 178:515-527 (1989) | | |
| | *162 | Lupu et al., "Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2" <u>Science</u> 249:1552-1555 (1990) | | |
| | *163 | Maeda et al., "Construction of Reshaped Human Antibodies with HIV-neutralizing Activity" <u>Hum. Antibod. Hybridomas</u> 2:124-134 (July 1991) | | |
| | *164 | Margni RA and Binaghi RA, "Nonprecipitating asymmetric antibodies" <u>Ann. Rev. Immunol.</u> 6:535-554 (1988) | | |
| | *165 | Margolies et al., "Diversity of light chain variable region sequences among rabbit antibodies elicited by the same antigens." <u>Proc. Natl. Acad. Sci. USA</u> 72:2180-84 (Jun 1975) | | |
| | *166 | Mariuzza et al., "The Structure Basis of Antigen-Antibody Recognition" <u>Ann. Rev. Biophys. Biophys. Chem</u> 16:139-159 (1987) | | |
| | *167 | Marquart et al., "Crystallographic refinement and atomic models of the intact immunoglobulin molecule Kol and its antigen-binding fragment at 3.0 A and 1.0 A resolution" <u>J. Mol. Biol.</u> 141(4):369-391 (Aug 25, 1980) | | |
| Examiner | | | Date Considered | |
| *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | |

09/705,680

Sheet 08 of 13

| | | | | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|------------------------------------|--------------------------------|
| FORM PTO-1449 | | U.S. Dept. of Commerce Patent and Trademark Office | | Atty Docket No. P0709P1D3 | Serial No. not yet assigned |
| LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary) | | | | Applicant Paul J. Carter et al. | |
| | | | | Filing Date 02 Nov 2000 | Group not yet assigned |
| OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | |
| | *168 | Mathieson et al., "Monoclonal-Antibody Therapy in Systemic Vasculitis" <u>New England J. of Medicine</u> pps. 250-254 (July 1990) | | | |
| | *169 | Matsumura et al., "Hydrophobic stabilization in T4 lysozyme determined directly by multiple substitutions of Ile 3" <u>Nature</u> 334:406-410 (1988) | | | |
| | *170 | Mian, IS et al., "Structure, function and properties of antibody binding sites" <u>J. Mol. Biol.</u> 217(1):133-151 (Jan 5, 1991) | | | |
| | *171 | Miller, R. et al., "Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma" <u>Blood</u> 62:988-995 (1983) | | | |
| | *172 | Morrison et al., "Chimeric Human Antibody Molecules: Mouse Antigen-binding Domains with Human Constant Region Domains" <u>Proc. Natl. Acad. Sci. USA</u> 81:6851-6855 (November 1984) | | | |
| | *173 | Morrison, S. L., "Transfectomas Provide Novel Chimeric Antibodies" <u>Science</u> 229:1202-1207 (September 20, 1985) | | | |
| | *174 | Nadler et al., "Immunogenicity of Humanized and Human Monoclonal Antibodies" <u>Clin. Pharmacology & Therapeutics</u> pps. 180 (Feb 1994) | | | |
| | *175 | Nakatani et al., "Humanization of mouse anti-human IL-2 receptor antibody B-B10" <u>Protein Engineering</u> 7:435-443 (1994) | | | |
| | *176 | Nelson, H., "Targeted Cellular Immunotherapy with Bifunctional Antibodies" <u>Cancer Cells</u> 3:163-172 (1991) | | | |
| | *177 | Neuberger et al., "A hapten-specific chimaeric IgE antibody with human physiological effector function" <u>Nature</u> 314:268-270 (March 21, 1985) | | | |
| | *178 | Neuberger et al., "Antibody Engineering" <u>Proceedings 8th Intl. Biotech. Symp., Paris II</u> :792-799 (1988) | | | |
| | *179 | Neuberger et al., "Recombinant Antibodies Possessing Novel Effector Functions" <u>Nature</u> 312:604-608 (December 13, 1984) | | | |
| | *180 | Newmark, P., "Making Chimeric Antibodies Even More Human" <u>Bio/Technology</u> 6:468 (May 1988) | | | |
| | *181 | Nishimura et al., "Human c-erbB-2 Proto-Oncogene Product as a Target for Bispecific-Antibody-Directed Adoptive Tumor Immunotherapy" <u>Int. J. Cancer</u> 50:800-804 (1992) | | | |
| | *182 | Nitta et al., "Preliminary trial of specific targeting therapy against malignant glioma" <u>Lancet</u> 335(8686):368-371 (Feb 17, 1990) | | | |
| | *183 | Nitta, T. et al., "Bispecific F(ab') ₂ monomer prepared with anti-CD3 and anti-tumor monoclonal antibodies is most potent in induction of cytotoxicity of human T cells" <u>European Journal of Immunology</u> 19:1437-1441 (1989) | | | |
| | *184 | Nolan et al., "Bifunctional antibodies: concept, production and applications" <u>Biochimica et Biophysica Acta</u> 1040:1-11 (1990) | | | |
| | *185 | Novotny et al., "Structural invariants of antigen binding: comparison of immunoglobulin VL-VH and VL-VL domain dimers" <u>Proc. Natl. Acad. Sci. USA</u> 82(14):4592-4596 (Jul 1985) | | | |
| | *186 | O'Connor et al., "Calcium Dependence of an Anti-Protein C Humanized Antibody Involves Framework Residues" (manuscript) | | | |
| | *187 | Ohtomo et al., "Humanization of Mouse ONS-M21 Antibody with the Aid of Hybrid Variable Regions" <u>Molecular Immunology</u> 32:407-416 (1995) | | | |
| Examiner | | | | Date Considered | |
| *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | |

09/05/84

Sheet 09 of 13

| | | | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|--------------------------------|
| FORM PTO-1449 | | U.S. Dept. of Commerce Patent and Trademark Office | Atty Docket No. P0709P1D3 | Serial No. not yet assigned |
| LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary) | | | Applicant Paul J. Carter et al. | |
| | | | Filing Date 02 Nov 2000 | Group not yet assigned |
| OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) | | | | |
| | *188 | Orlandi et al., "Cloning Immunoglobulin Variable Domains for Expression by the Polymerase Chain Reaction" <u>Proc. Natl. Acad. Sci. USA</u> 86:3833-3837 (May 1989) | | |
| | *189 | Orlandi et al., "Cloning of cDNA Corresponding to Heavy and Light Chain Immunoglobulin Variable Domains" <u>Protein and Pharmaceutical Engineering</u> pps. 90 (1989) | | |
| | *190 | Ostberg & Queen, "Human and humanized monoclonal antibodies: preclinical studies and clinical experience" <u>Biochem. Soc. Transactions</u> pps. 1038-1043 (1995) | | |
| | *191 | Padlan et al., "Model-Building Studies of Antigen-Binding Sites: The Hapten-Binding Site of MOPC-315" <u>C.S. Harbor Symp. Quant. Biol.</u> 41:627-637 (1977) | | |
| | *192 | Padlan et al., "Model-building Studies of Antigen-binding Sites: The Hapten-binding Site of MOPC-315" <u>Cold Springs Harbor Symposia On Quantitative Biology</u> XLI:627-637 (1977) | | |
| | *193 | Padlan, E., "Anatomy of the Antibody Molecule" <u>Molecular Immunology</u> 31(3):169-217 (1994) | | |
| | *194 | Padlan, E., "Evaluation of the Structural Variation Among Light Chain Variable Domains" <u>Molecular Immunology</u> 16:287-296 (1979) | | |
| | *195 | Palm & Hilschmann, "Primary structure of a crystalline monoclonal immunoglobulin K-type L-chain, subgroup I (Bence-Jones preotin Rei); isolation & characterization of the tryptic peptides:..." <u>Hoppes-Sevler's Z. Physiol. Chem.</u> 356:167-191 (Feb 1975) | | |
| | *196 | Palm & Hilschmann, "The primary structure of a crystalline, monoclonal immunoglobulin-L-chain of the x-type, subgroup I (Bence-Jones Protein Rei): a contribution to the elucidation of the three-dimensional structure of the immunoglobulins" <u>Hoppe-Sevler's Z. Physiol. Chem.</u> 354:1651-1654 (Dec 1973) | | |
| | *197 | Panka et al., "Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies" <u>Proc. Natl. Acad. Sci. USA</u> 85:3080-3084 (May 1988) | | |
| | *198 | Pluckthun, Andreas, "Antibody engineering: advances from the use of escherichia coli expression systems" <u>Biotechnology</u> 9:545-51 (1991) | | |
| | *199 | "Polygen Corporation" in New Products, Chemical Design Automation 3" (November 1988) | | |
| | *200 | Presta et al., "Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders" <u>Cancer Research</u> 57(20):4593-4599 (Oct 15, 1997) | | |
| | *201 | Presta et al., "Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders" <u>Cancer Research</u> (in press) pps. 1-32 | | |
| | *202 | Presta et al., "Humanization of an Antibody Directed Against IgE" <u>J. Immunol.</u> 151(5):2623-2632 (September 1, 1993) | | |
| | *203 | Preval & Fougereau, "Specific Interaction between V _H and V _L Regions of Human Monoclonal Immunoglobulins" <u>J. Mol. Biol.</u> 102:657-678 (1976) | | |
| | *204 | Queen et al., "A humanized antibody that binds to the interleukin 2 receptor" <u>Proc. Natl. Acad. Sci. USA</u> 86(24):10029-10033 (December 1989) | | |
| | *205 | Queen et al., "Construction of Humanized Antibodies and Testing in Primates" <u>J. Cell. Biochem. Suppl.</u> 1: (Part E) (20th Ann. Mtg. Keystone Symp. Denver, CO Mar 10-16, 1991) pps. 137 (1991) | | |
| | *206 | Queen et al., "Humanised antibodies to the IL-2 receptor" <u>Protein Eng. Antibody Mol. Prophyl. Ther. Appl. Man.</u> Clark, M., Nottingham, UK: Academic Titles pps. 159-70 (1993) | | |
| | *207 | Rhodes & Birch, "Large-Scale Production of Proteins from Mammalian Cells" <u>Bio/Technology</u> 6:518, 521, 52 (May 1988) | | |
| Examiner | | | Date Considered | |
| *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | |

09/705,684

Sheet 10 of 13

| | | | | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|------------------------------------|--------------------------------|
| FORM PTO-1449 | | U.S. Dept. of Commerce Patent and Trademark Office | | Atty Docket No. P0709P1D3 | Serial No. not yet assigned |
| LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary) | | | | Applicant Paul J. Carter et al. | |
| | | | | Filing Date 02 Nov 2000 | Group not yet assigned |
| OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | |
| | *208 | Riechmann & Winter, "Recombinant Antibodies" (U. of London Royal Postgraduate Medical School, Wolfson Institute, Abstract) (May 1987) | | | |
| | *209 | Riechmann et al., "Expression of an Antibody Fv Fragment in Myeloma Cells" <u>J. Mol. Biol.</u> 203:825-828 (1988) | | | |
| | *210 | Riechmann et al., <u>Alignment of VL Sequences</u> (1988) | | | |
| | *211 | Riechmann et al., "Reshaping Human Antibodies for Therapy" <u>Nature</u> 332:323-327 (Mar 24, 1988) | | | |
| | *212 | Riechmann, "Declaration" from EP Opposition to EP Patent No. 451,261 B1 (Oct 22, 1996) | | | |
| | *213 | Riechmann, "Humanizing of Recombinant Antibodies" (Intl. Symp. on Clin. Appl. of Monoclonal Antibodies, Guildford, England) pps. 33-34 (Sep 1987) | | | |
| | *214 | Roberts & Rees, "Generation of an antibody with enhanced affinity and specificity for its antigen by protein engineering" <u>Nature</u> 328:731-734 (Aug 1987) | | | |
| | *215 | Rodrigues et al., "Engineering a humanized Bispecific F(ab') ₂ fragment for improved binding to T cells" <u>Int. J. Cancer</u> (Suppl.) 7:45-50 (1992) | | | |
| | *216 | Roitt et al., <u>Immunology</u> (Gower Medical Publishing Ltd., London, England) pps. 5-5 (1985) | | | |
| | *217 | Rostapshov et al., "Effective method for obtaining long nucleotide chains on partially complementary templates" <u>FEBS Letters</u> 249(2):379-382 (Jun 1989) | | | |
| | *218 | Routledge et al., "A Humanized Monovalent CD3 Antibody which Can Activate Homologous Complement" <u>European Journal of Immunology</u> 21:2717-2725 (1991) | | | |
| | *219 | Saul et al., "Preliminary refinement and structural analysis of the Fab fragment from human immunoglobulin new at 2.0 A resolution" <u>Journal of Biological Chemistry</u> 253(2):585-597 (January 25, 1978) | | | |
| | *220 | Schneider et al., "The Anti-Idiotypic Response by Cynomolgus Monkeys to Humanized Anti-Tac Is Primarily Directed to Complementarity-Determining Regions H1, H2, and L3" <u>J. of Immunology</u> 150:3086-3090 (Apr 1993) | | | |
| | *221 | Schroff, R. et al., "Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy" <u>Cancer Research</u> 45:879-885 (1985) | | | |
| | *222 | Sedlacek et al., "Monoclonal Antibodies in Tumor Therapy", Karger pps. 119-126, 133-179 (1988) | | | |
| | *223 | Segal et al., "The three-dimensional structure of a phosphorylcholine-binding mouse immunoglobulin Fab and the nature of the antigen binding site" <u>Proc. Natl. Acad. Sci. USA</u> 71(11):4298-4302 (Nov 1974) | | | |
| | *224 | Sha et al., "A Heavy-Chain Grafted Antibody that Recognizes the Tumor-Associated TAG72 Antigen" <u>Cancer Biotherapy</u> 9:341-349 (1994) | | | |
| | *225 | Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene" <u>Journal of Experimental Medicine</u> 175:217-225 (Jan 1, 1992) | | | |
| | *226 | Shearman et al., "Construction, Expression and Characterization of Humanized Antibodies Directed Against the Human α/β T Cell Receptor" <u>J. Immunol.</u> 147(12):4366-4373 (December 15, 1991) | | | |
| | *227 | Shepard and Lewis, "Resistance of tumor cells to tumor necrosis factor" <u>J. Clin. Immunol.</u> 8(5):333-395 (1988) | | | |
| Examiner | | | | Date Considered | |
| *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | |

091/705,686

| | | | | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|--|------------------------------------|--------------------------------|
| FORM PTO-1449 LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary) | | U.S. Dept. of Commerce Patent and Trademark Office | | Atty Docket No. P0709P1D3 | Serial No. not yet assigned |
| | | | | Applicant Paul J. Carter et al. | |
| | | | | Filing Date 02 Nov 2000 | Group not yet assigned |
| OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | |
| *228 | Sheriff et al., "Three-dimensional structure of an antibody-antigen complex" <u>Proc. Natl. Acad. Sci. USA</u> 84(22):8075-8079 (Nov. 1987) | | | | |
| *229 | Sherman et al., "Haloperidol binding to monoclonal antibodies" <u>Journal of Biological Chemistry</u> 263:4064-4074 (1988) | | | | |
| *230 | Shields et al., "Inhibition of Allergic Reactions with Antibodies to IgE" <u>International Archives of Allergy and Immunology</u> 107(1-3):308-312 (May 1995) | | | | |
| *231 | Silvertown et al., "Three-dimensional structure of an intact human immunoglobulin" <u>Proc. Natl. Acad. Sci. USA</u> 74:5140-5144 (1977) | | | | |
| *232 | Sims et al., "A Humanized CD18 Antibody Can Block Function Without Cell Destruction" <u>The Journal of Immunology</u> 151(4):2296-2308 (Aug 1993) | | | | |
| *233 | Slamon et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene" <u>Science</u> 235:177-182 (Jan 9, 1987) | | | | |
| *234 | Slamon et al., "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer" <u>Science</u> 244:707-712 (May 12, 1989) | | | | |
| *235 | Smith-Gill et al., "A Three-dimensional Model of an Anti-lysozyme Antibody" <u>Mol. Biol.</u> 194:713-724 (1987) | | | | |
| *236 | Snow and Amzel, "Calculating three-dimensional changes in protein structure due to amino-acid substitutions: the variable region of immunoglobulins" <u>Protein: Structure, Function, and Genetics</u> , Alan R. Liss, Inc. Vol. 1:267-279 (1986) | | | | |
| *237 | Songvilai et al., "Bispecific antibody: a tool for diagnosis and treatment of disease" <u>Clin. Exp. Immunol.</u> 79:315-321 (1990) | | | | |
| *238 | Sox et al., "Attachment of carbohydrate to the variable region of myeloma immunoglobulin light chains" <u>Proc. Natl. Acad. Sci. USA</u> 66:975-82 (July 1970) | | | | |
| *239 | Spiegelberg et al., "Localization of the carbohydrate within the variable region of light and heavy chains of human YG myeloma proteins" <u>Biochemistry</u> 9:4217-23 (Oct 1970) | | | | |
| *240 | Stanford, "A Predictive Method for Determining Possible Three-dimensional Foldings of Immunoglobulin Backbones Around Antibody Combining Sites" <u>Theor. Biol.</u> 88:421-439 (1981) | | | | |
| *241 | Stickney et al., "Bifunctional Antibody: ZCE/CHA ¹¹¹ Indium BLEDTA-IV Clinical Imaging in Colorectal Carcinoma" <u>Antibody, Immuno Radiopharm</u> 2:1-13 (1989) | | | | |
| *242 | Takeda et al., "Construction of Chimaeric Processed Immunoglobulin Genes Containing Mouse Variable and Human Constant Region Sequences" <u>Nature</u> 314(6010):452-454 (April 4, 1985) | | | | |
| *243 | Tao et al., "Studies of aglycosylated chimeric mouse-human IgG. Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region" <u>Journal of Immunology</u> 143(8):2595-2601 (Oct 15, 1989) | | | | |
| *244 | Tempest et al., "Identification of framework residues required to restore antigen binding during reshaping of a monoclonal antibody against the glycoprotein gB of human cytomegalovirus" <u>Int. J. Biol. Macromol.</u> 17:37-42 (1995) | | | | |
| *245 | Tempest et al., "Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection In Vivo" <u>Bio/Technology</u> 9:266-271 (March 1991) | | | | |
| *246 | Tighe et al., "Delayed Allograft Rejection in Primates Treated with Anti-IL-2 Receptor Monoclonal antibody Campath-6" <u>Transplantation</u> 45(1):226-228 (Jan 1988) | | | | |
| *247 | Tramontano et al., "Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the V _H domains of immunoglobulins" <u>J. Mol. Biol.</u> 215(1):175-182 (Sep 5, 1990) | | | | |
| Examiner | | | | Date Considered | |
| *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | |

09/705,686

Sheet 12 of 13

| | | | | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|------------------------------------|--------------------------------|
| FORM PTO-1449 | | U.S. Dept. of Commerce Patent and Trademark Office | | Atty Docket No. P0709P1D3 | Serial No. not yet assigned |
| LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary) | | | | Applicant Paul J. Carter et al. | |
| | | | | Filing Date 02 Nov 2000 | Group not yet assigned |
| OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | |
| | *248 | Tramontano, "Structural Determinants of the Conformations of Medium-Sized Loops in Proteins" <u>Proteins</u> 6:382-394 (1989) | | | |
| | *249 | Uchiyama et al., "A Monoclonal Antibody (ANTI-Tac) Reactive with Activated and Functionally Mature Human T Cells" <u>Journal of Immunology</u> 126:1393-1397 (1981) | | | |
| | *250 | Verhoeyen & Riechmann, "Engineering of Antibodies" <u>BioEssays</u> 8(2):74-78 (Feb/Mar 1988) | | | |
| | *251 | Verhoeyen et al., "Grafting Hypervariable Regions in Antibodies" <u>Protein Structure, Folding, and Design</u> 2 (Proc. DuPont-UCLA Symp. Streamboat Springs, CO, Apr 4-11, 1987), Dale L. Oxender, New York:Alan R. Liss, Inc. pps. 501-502 (1987) | | | |
| | *252 | Verhoeyen et al., "Humanising Mouse Antibodies: A Protein Engineering Approach" <u>Soc. for Analytical Cytology</u> (XIth Intl. Mtg. for the Soc. for Analytical Cytology, Cambridge, UK) pps. 22 and slide presented at mtg | | | |
| | *253 | Verhoeyen et al., "Re-shaped human anti-PLAP antibodies" <u>Monoclonal Antibodies Applications in Clinical Oncology</u> , Epenetos, 1st edition, Chapman & Hall Medical pps. 37-43 (1991) | | | |
| | *254 | Verhoeyen et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity" <u>Science</u> 239:1534-1536 (Mar 25, 1988) | | | |
| | *255 | Vincenti et al., "Interleukin-2-Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation" <u>New Engl. J. Med.</u> 338:161-165 (1998) | | | |
| | *256 | Vitetta et al., "Redesigning Nature's Poisons to Create Anti-Tumor Reagents" <u>Science</u> 238:1098-1104 (1987) | | | |
| | *257 | Waldmann et al., "Interleukin 2 Receptor (Tac Antigen) Expression in HTLV-1-associated Adult T-Cell Leukemia" <u>Cancer Research</u> 45:4559s-4562s (1985) | | | |
| | *258 | Waldmann, T., "Monoclonal Antibodies in Diagnosis and Therapy" <u>Science</u> 252:1657-1662 (June 1991) | | | |
| | *259 | Waldmann, Thomas A., "The Structure, Function, and Expression of Interleukin-2 Receptors on Normal and Malignant Lymphocytes" <u>Science</u> 232:727-732 (1986) | | | |
| | *260 | Wallick et al., "Glycosylation of a VH residue of a monoclonal antibody against alpha (1---6) dextran increases its affinity for antigen" <u>Journal of Experimental Medicine</u> 168(3):1099-1109 (Sep 1988) | | | |
| | *261 | Ward et al., "Expression and Secretion of Repertoires of VH Domains in Escherichia Coli: Isolation of Antigen Binding Activities" <u>Progress in Immunology</u> (7th Intl. Congress Immunol. Berlin, W. Germany), F. Melchers Vol. VII:1144-1151 (1989) | | | |
| | *262 | Ward, E.S. et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli" <u>Nature</u> 341:544-546 (1989) | | | |
| | *263 | Werther et al., "Humanization of an Anti-Lymphocyte Function-Associated Antigen (LFA)-1 Monoclonal Antibody and Reengineering of the Humanized Antibody for Binding to Rhesus LFA-1" <u>J. of Immunology</u> 157:4986-4995 (1996) | | | |
| | *264 | Whittle et al., "Construction and Expression of A CDR-Grafted Anti-TNF Antibody" <u>J. Cell Biochem. Suppl</u> Q (Symp. on Protein and Pharm. Eng. Mol. and Cell. Biol. Park City, Utah)13 Part A:96 (1989) | | | |
| | *265 | Winter & Neuberger, "Restructuring Enzymes and Antibodies" <u>Investigation and Exploitation of Antibody Combining Sites</u> , Eric Reid, Plenum Press pps. 139-140 (1985) | | | |
| | *266 | Winter and Milstein, "Man-made antibodies" <u>Nature</u> 349(6307):293-299 (Jan 24, 1991) | | | |
| | *267 | Winter et al., "Protein Engineering by Site Directed Mutagenesis" <u>Chemical Synthesis in Molecular Biology</u> , H. Blocker et al., VCH pps. 189-197 (1987) | | | |
| Examiner | | | | Date Considered | |
| *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | |

USCOMM-DC 80-398.